Tryptophan

Function

Amino acids, including tryptophan, are used as building blocks in protein biosynthesis, and proteins are required to sustain life. Tryptophan is among the less common amino acids found in proteins, but it plays important structural or functional roles whenever it occurs. For instance, tryptophan and tyrosine residues play special roles in "anchoring" membrane proteins within the cell membrane. Tryptophan, along with other aromatic amino acids, is also important in glycan-protein interactions. In addition, tryptophan functions as a biochemical precursor for the following compounds:

• Serotonin (a neurotransmitter), synthesized by tryptophan hydroxylase.
• Melatonin (a neurohormone) is in turn synthesized from serotonin, via N-acetyltransferase and 5-hydroxyindole-O-methyltransferase enzymes.
• Kynurenine, to which tryptophan is mainly (more than 95%) metabolized. Two enzymes, namely indoleamine 2,3-dioxygenase (IDO) in the immune system and the brain, and tryptophan 2,3-dioxygenase (TDO) in the liver, are responsible for the synthesis of kynurenine from tryptophan. The kynurenine pathway of tryptophan catabolism is altered in several diseases, including psychiatric disorders such as schizophrenia, major depressive disorder, and bipolar disorder.
• Niacin, also known as vitamin B3, is synthesized from tryptophan via kynurenine and quinolinic acids.
• Auxins (a class of phytohormones) are synthesized from tryptophan.

The disorder fructose malabsorption causes improper absorption of tryptophan in the intestine, reduced levels of tryptophan in the blood, and depression.

In bacteria that synthesize tryptophan, high cellular levels of this amino acid activate a repressor protein, which binds to the trp operon. Binding of this repressor to the tryptophan operon prevents transcription of downstream DNA that codes for the enzymes involved in the biosynthesis of tryptophan. So high levels of tryptophan prevent tryptophan synthesis through a negative feedback loop, and when the cell's tryptophan levels go down again, transcription from the trp operon resumes. This permits tightly regulated and rapid responses to changes in the cell's internal and external tryptophan levels.

Recommended dietary allowance

In 2002, the U.S. Institute of Medicine set a Recommended Dietary Allowance (RDA) of 5 mg/kg body weight/day of tryptophan for adults 19 years and over.

Dietary sources

Tryptophan is present in most protein-based foods or dietary proteins. It is particularly plentiful in chocolate, oats, dried dates, milk, yogurt, cottage cheese, red meat, eggs, fish, poultry, sesame, legumes such as chickpeas and soybeans, almonds, sunflower seeds, pumpkin seeds, hemp seeds, buckwheat, spirulina, and peanuts. Contrary to the popular belief that cooked turkey contains an abundance of tryptophan, the tryptophan content in turkey is typical of poultry.

Medical use

Depression

Because tryptophan is converted into 5-hydroxytryptophan (5-HTP) which is then converted into the neurotransmitter serotonin, it has been proposed that consumption of tryptophan or 5-HTP may improve depression symptoms by increasing the level of serotonin in the brain. Tryptophan is sold over the counter in the United States (after being banned to varying extents between 1989 and 2005) and the United Kingdom as a dietary supplement for use as an antidepressant, anxiolytic, and sleep aid. It is also marketed as a prescription drug in some European countries for the treatment of major depression. There is evidence that blood tryptophan levels are unlikely to be altered by changing the diet, but consuming purified tryptophan increases the serotonin level in the brain, whereas eating foods containing tryptophan does not.

In 2001 a Cochrane review of the effect of 5-HTP and tryptophan on depression was published. The authors included only studies of a high rigor and included both 5-HTP and tryptophan in their review because of the limited data on either. Of 108 studies of 5-HTP and tryptophan on depression published between 1966 and 2000, only two met the authors' quality standards for inclusion, totaling 64 study participants. The substances were more effective than placebo in the two studies included but the authors state that "the evidence was of insufficient quality to be conclusive" and note that "because alternative antidepressants exist which have been proven to be effective and safe, the clinical usefulness of 5-HTP and tryptophan is limited at present". The use of tryptophan as an adjunctive therapy in addition to standard treatment for mood and anxiety disorders is not supported by the scientific evidence.

Insomnia

The American Academy of Sleep Medicine's 2017 clinical practice guidelines recommended against the use of tryptophan in the treatment of insomnia due to poor effectiveness.

Side effects

Potential side effects of tryptophan supplementation include nausea, diarrhea, drowsiness, lightheadedness, headache, dry mouth, blurred vision, sedation, euphoria, and nystagmus (involuntary eye movements).

Interactions

Tryptophan taken as a dietary supplement (such as in tablet form) has the potential to cause serotonin syndrome when combined with antidepressants of the MAOI or SSRI class or other strongly serotonergic drugs. Because tryptophan supplementation has not been thoroughly studied in a clinical setting, its interactions with other drugs are not well known.

Isolation

The isolation of tryptophan was first reported by Frederick Hopkins in 1901. Hopkins recovered tryptophan from hydrolysed casein, recovering 4–8 g of tryptophan from 600 g of crude casein.

Biosynthesis and industrial production

Tryptophan is not synthesized from simpler substances in humans and other animals and is sourced from dietary intake of tryptophan-containing proteins. Plants and microorganisms commonly synthesize tryptophan from shikimic acid or anthranilate. Tryptophan biosynthesis starts with the condensation of anthranilate with phosphoribosylpyrophosphate (PRPP), generating pyrophosphate as a by-product. The ring of the ribose moiety is opened and subjected to reductive decarboxylation, producing indole-3-glycerol phosphate; this, in turn, is transformed into indole. In the last step, tryptophan synthase catalyzes the formation of tryptophan from indole and the amino acid serine.

:[[Image:Tryptophan biosynthesis (en).svg|class=skin-invert-image|900px]]

The industrial production of tryptophan is also biosynthetic and is based on the fermentation of serine and indole using either wild-type or genetically modified bacteria such as B. amyloliquefaciens, B. subtilis, C. glutamicum or E. coli. These strains carry mutations that prevent the reuptake of aromatic amino acids or multiple/overexpressed trp operons. The conversion is catalyzed by the enzyme tryptophan synthase.

Society and culture

Showa Denko contamination scandal

Main article: Eosinophilia–myalgia syndrome

There was a large outbreak of eosinophilia-myalgia syndrome (EMS) in the U.S. in 1989, with more than 1,500 cases reported to the CDC and at least 37 deaths. After preliminary investigation revealed that the outbreak was linked to intake of tryptophan, the U.S. Food and Drug Administration (FDA) recalled tryptophan supplements in 1989 and banned most public sales in 1990, with other countries following suit.

Subsequent studies suggested that EMS was linked to specific batches of L-tryptophan supplied by a single large Japanese manufacturer, Showa Denko. It eventually became clear that recent batches of Showa Denko's L-tryptophan were contaminated by trace impurities, which were subsequently thought to be responsible for the 1989 EMS outbreak. However, other evidence suggests that tryptophan itself may be a potentially major contributory factor in EMS. There are also claims that a precursor reached sufficient concentrations to form a toxic dimer.

The FDA loosened its restrictions on sales and marketing of tryptophan in February 2001,

The fact that the Showa Denko facility used genetically engineered bacteria to produce the contaminated batches of L-tryptophan later found to have caused the outbreak of eosinophilia-myalgia syndrome has been cited as evidence of a need for "close monitoring of the chemical purity of biotechnology-derived products". Those calling for purity monitoring have, in turn, been criticized as anti-GMO activists who overlook possible non-GMO causes of contamination and threaten the development of biotech.

Turkey meat and drowsiness hypothesis

A common assertion in the US and the UK is that heavy consumption of turkey meat—as seen during Thanksgiving and Christmas—results in drowsiness, due to high levels of tryptophan contained in turkey. However, the amount of tryptophan in turkey is comparable with that of other meats. Drowsiness after eating may be caused by other foods eaten with the turkey, particularly carbohydrates. Ingestion of a meal rich in carbohydrates triggers the release of insulin. Insulin in turn stimulates the uptake of large neutral branched-chain amino acids (BCAA), but not tryptophan, into muscle, increasing the ratio of tryptophan to BCAA in the blood stream. The resulting increased tryptophan ratio reduces competition at the large neutral amino acid transporter (which transports both BCAA and aromatic amino acids), resulting in more uptake of tryptophan across the blood–brain barrier into the cerebrospinal fluid (CSF). Once in the CSF, tryptophan is converted into serotonin in the raphe nuclei by the normal enzymatic pathway. The resultant serotonin is further metabolised into the hormone melatonin—which is an important mediator of the circadian rhythm—by the pineal gland. Hence, these data suggest that "feast-induced drowsiness"—or postprandial somnolence—may be the result of a heavy meal rich in carbohydrates, which indirectly increases the production of melatonin in the brain, and thereby promotes sleep.

Research

Yeast amino acid metabolism

In 1912 Felix Ehrlich demonstrated that yeast metabolizes the natural amino acids essentially by splitting off carbon dioxide and replacing the amino group with a hydroxyl group. By this reaction, tryptophan gives rise to tryptophol.

Serotonin precursor

Tryptophan affects brain serotonin synthesis when given orally in a purified form and is used to modify serotonin levels for research. Low brain serotonin level is induced by administration of tryptophan-poor protein in a technique called acute tryptophan depletion. Studies using this method have evaluated the effect of serotonin on mood and social behavior, finding that serotonin reduces aggression and increases agreeableness.

Psychedelic effects

Tryptophan produces the head-twitch response (HTR) in rodents when administered at sufficiently high doses. The HTR is induced by serotonergic psychedelics like lysergic acid diethylamide (LSD) and psilocybin and is a behavioral proxy of psychedelic effects. Tryptophan is converted into the trace amine tryptamine and tryptamine is N-methylated by indolethylamine N-methyltransferase (INMT) into N-methyltryptamine (NMT) and N,N-dimethyltryptamine (N,N-DMT), which are known serotonergic psychedelics.

Fluorescence

Main article: Fluorescence spectroscopy#Tryptophan fluorescence

Tryptophan is an important intrinsic fluorescent probe (amino acid), which can be used to estimate the nature of the microenvironment around the tryptophan residue. Most of the intrinsic fluorescence emissions of a folded protein are due to excitation of tryptophan residues.

References

References

1. (2012). "Single-crystal investigation of L-tryptophan with ''{{prime". [[Acta Crystallographica Section B]].
2. (1969). "Data for Biochemical Research". Clarendon Press.
3. (2002). "Conversion of L-tryptophan to serotonin and melatonin in human melanoma cells". FEBS Letters.
4. "L-tryptophan {{!}} C11H12N2O2 - PubChem".
5. Curzon, G.. (1987-12-31). "Hopkins and the Discovery of Tryptophan". De Gruyter.
6. (10 July 1968). "IUPAC-IUB Commission on Biochemical Nomenclature A One-Letter Notation for Amino Acid Sequences". Journal of Biological Chemistry.
7. (1983). "Role of precursor availability in control of monoamine biosynthesis in brain". Physiological Reviews.
8. (1990). "Serotonin release varies with brain tryptophan levels". Brain Research.
9. (1969). "The mammalian pineal as a neuroendocrine transducer". Recent Progress in Hormone Research.
10. (2020-11-23). "The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies". Molecular Psychiatry.
11. (19 October 2020). "The kynurenine pathway in bipolar disorder: a meta-analysis on the peripheral blood levels of tryptophan and related metabolites.". Molecular Psychiatry.
12. (1965). "Studies on the biosynthesis of nicotinamide adenine dinucleotide. II. A role of picolinic carboxylase in the biosynthesis of nicotinamide adenine dinucleotide from tryptophan in mammals". The Journal of Biological Chemistry.
13. (2008). "A new gene for auxin synthesis". Cell.
14. (2001). "Fructose malabsorption is associated with decreased plasma tryptophan". Scandinavian Journal of Gastroenterology.
15. (June 1998). "Fructose malabsorption is associated with early signs of mental depression". European Journal of Medical Research.
16. (2005). "Complexity in regulation of tryptophan biosynthesis in Bacillus subtilis". Annual Review of Genetics.
17. (2002). "Dietary Reference Intakes for Energy, Carbohydrates, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids". The National Academies Press.
18. (2007-11-21). "Does Turkey Make You Sleepy?".
19. Holden, Joanne. "USDA National Nutrient Database for Standard Reference, Release 22". Nutrient Data Laboratory, Agricultural Research Service, United States Department of Agriculture.
20. (2002). "[The contribution of cocoa additive to cigarette smoking addiction]". The National Institute for Public Health and the Environment (Netherlands).
21. (2011). "Tryptophan and depression: can diet alone be the answer?". Acta Neuropsychiatrica.
22. (2012). "Effects and side effects associated with the non-nutritional use of tryptophan by humans". The Journal of Nutrition.
23. (1980). "Precursor control of neurotransmitter synthesis". Pharmacological Reviews.
24. (2002). "Tryptophan and 5-hydroxytryptophan for depression". The Cochrane Database of Systematic Reviews.
25. (September 2013). "Complementary and alternative therapies as add-on to pharmacotherapy for mood and anxiety disorders: a systematic review". Journal of Affective Disorders.
26. (February 2017). "Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline". J Clin Sleep Med.
27. (December 2012). "Summary of workshop discussions on establishing upper limits for amino acids with specific attention to available data for the essential amino acids leucine and tryptophan". The Journal of Nutrition.
28. (June 2012). "Dietary supplement drug therapies for depression". Journal of Psychosocial Nursing and Mental Health Services.
29. (December 1901). "A contribution to the chemistry of proteids: Part I. A preliminary study of a hitherto undescribed product of tryptic digestion". The Journal of Physiology.
30. (1930). "L-Tryptophane". Org. Synth..
31. (1995). "Tryptophan biosynthesis and metabolism: biochemical and molecular genetics". The Plant Cell.
32. (2002). "Microbial Production of l-Amino Acids".
33. (2012). "Bio-based production of chemicals, materials and fuels -Corynebacterium glutamicum as versatile cell factory". Current Opinion in Biotechnology.
34. (2008). "Engineering the spatial organization of metabolic enzymes: mimicking nature's synergy". Current Opinion in Biotechnology.
35. (2014). "Encyclopedia of Toxicology". Elsevier Science.
36. (2001-02-01). "Information Paper on L-tryptophan and 5-hydroxy-L-tryptophan". FU. S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, Office of Nutritional Products, Labeling, and Dietary Supplements.
37. (2017-05-12). "L-tryptophan: Uses and Risks".
38. (27 April 1990). "Studies Tie Disorder to Maker of Food Supplement". The New York Times.
39. (1991). "["Eosinophilia-myalgia" syndrome due to L-tryptophan containing products. Cooperative evaluation of French Regional Centers of Pharmacovigilance. Analysis of 24 cases].". Thérapie.
40. (June 2004). "COT Statement on Tryptophan and the Eosinophilia-Myalgia Syndrome". UK Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment.
41. (July 1990). "Eosinophilia-myalgia syndrome associated with exposure to tryptophan from a single manufacturer". JAMA.
42. (April 1993). "Risk factors for developing eosinophilia myalgia syndrome among L-tryptophan users in New York". The Journal of Rheumatology.
43. (October 1996). "Tryptophan produced by Showa Denko and epidemic eosinophilia-myalgia syndrome". The Journal of Rheumatology. Supplement.
44. (January 1992). "Identification of substances formed by decomposition of peak E substance in tryptophan". Food and Chemical Toxicology.
45. (November 2005). "A heretofore undisclosed crux of eosinophilia-myalgia syndrome: compromised histamine degradation". Inflammation Research.
46. Michael Predator Carlton. "Molecular Biology and Genetic Engineering explained by someone who's done it".
47. (September 1994). "Eosinophilia-myalgia syndrome and tryptophan production: a cautionary tale". Trends in Biotechnology.
48. (November 1990). "Does medical mystery threaten biotech?". Science.
49. Harding, Nick. (2023-12-21). "How to stop Christmas food from ruining your sleep". The Telegraph.
50. "Chemistry.org: Thanksgiving, Turkey, and Tryptophan".
51. (September 1992 }}{{dead link). "Food & mood. (neuroscience professor Richard Wurtman) (Interview)". Nutrition Action Healthletter.
52. (March 1988). "Serotonin precursor influenced by type of carbohydrate meal in healthy adults". The American Journal of Clinical Nutrition.
53. (January 2003). "Effects of normal meals rich in carbohydrates or proteins on plasma tryptophan and tyrosine ratios". The American Journal of Clinical Nutrition.
54. (February 2007). "High-glycemic-index carbohydrate meals shorten sleep onset". The American Journal of Clinical Nutrition.
55. (2012). "Insulin in the Brain: There and Back Again". Pharmacology & Therapeutics.
56. (August 1975). "Kinetic analysis of blood-brain barrier transport of amino acids". Biochimica et Biophysica Acta (BBA) - Biomembranes.
57. (May 1984). "Diurnal variations in plasma concentrations of basic and neutral amino acids and in red cell concentrations of aspartate and glutamate: effects of dietary protein intake". The American Journal of Clinical Nutrition.
58. (1971). "Brain serotonin content: increase following ingestion of carbohydrate diet". Science.
59. Atul Khullar, M. D.. (2012-07-10). "The Role of Melatonin in the Circadian Rhythm Sleep-Wake Cycle". Psychiatric Times.
60. (1930). "A synthesis of tryptophol". Journal of Biological Chemistry.
61. (September 2013). "Acute tryptophan depletion in humans: a review of theoretical, practical and ethical aspects". Journal of Psychiatry & Neuroscience.
62. (2013). "The effect of raising and lowering tryptophan levels on human mood and social behaviour". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences.
63. (2018). "Behavioral Neurobiology of Psychedelic Drugs".
64. (2012). "Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model". Drug Test Anal.
65. (2013). "The Neuroscience of Hallucinations". Springer New York.
66. (September 2016). "Neuropharmacology of N,N-dimethyltryptamine". Brain Res Bull.
67. (2018). "N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function". Front Neurosci.
68. (October 2018). "Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT)". ACS Chem Neurosci.
69. (26 February 2024). "The Clinical Potential of Dimethyltryptamine: Breakthroughs into the Other Side of Mental Illness, Neurodegeneration, and Consciousness". MDPI AG.
70. (August 2015). "The hallucinogenic world of tryptamines: an updated review". Arch Toxicol.